Most autoimmune drugs suppress the immune system broadly and accept the infection risk. Merida’s platform aims to destroy only the specific antibodies causing disease — and Lilly paid up to $2.9B for it.
CAR-T produced drug-free remission in lupus and rheumatoid arthritis. Then three cases of a rare hyperinflammatory syndrome appeared, and two of the largest programmes stopped.
Six patients who had failed up to eight biologics over a decade. Three of them off all medication, in remission, a year later — from a single infusion of engineered cells.
Fish oil and low-dose aspirin matched a course of antibiotics for severe gum disease over a year — 57.7% versus 58% reaching the clinical goal, against 23.1% for cleaning alone.
Over 90% of health systems have deployed third-party AI. Fewer than half can properly test it before it touches patients — and 63% describe their strategy as ad hoc.
Brief nightly stirrings you never notice tracked with genetic Alzheimer’s risk in middle-aged adults — pointing at a brainstem region that is among the first places the disease appears.
Earlier tricuspid repair trials showed patients felt better and nothing more. TRIC-I-HF cut death and heart-failure hospitalisation by 60% — the first hard-endpoint win for the forgotten valve.
Every participant lost the same 10% of body weight. Only the ketogenic group cut liver fat by two-thirds — and their cholesterol did not rise, which surprised the researchers most.
Peripheral nerves regrow. Spinal cord nerves largely do not. Mount Sinai researchers found a receptor that actively holds regeneration back — and drugs that block it are already in human trials for other diseases.
A 30% cut in cardiovascular events in healthy over-70s — and no difference in disability-free survival. Both findings are the trial’s result, and older adults may care more about the second.
Two partial responses and six patients with stable disease out of 28. Aprea is expanding the trial — and being unusually direct that the goal is finding out who responds before committing to Phase 2.
A single small tablet, once daily — aimed specifically at people whose resistance or drug interactions had kept them on complex multi-pill regimens everyone else moved on from.